Key TakeawaysThe FDA has granted Priority Review to Enhertu for the treatment of HER2-low and HER2-ultralow metastatic breast cancer, based on positive results...
Key TakeawaysThe MILOS study demonstrated that bempedoic acid significantly reduced LDL-C levels by 30.3% over two years, improving cholesterol management in patients with...
Datopotamab Deruxtecan Fails to Achieve OS Benefit in Breast Cancer Trial, But Shows PFS Gains
Key TakeawaysDatopotamab deruxtecan (Dato-DXd) did not reach statistical significance for overall survival (OS) in the TROPION-Breast01 Phase III trial.
The trial had previously...
Key TakeawaysThe HERTHENA-Lung02 phase 3 trial demonstrated that patritumab deruxtecan significantly improved progression-free survival (PFS) in patients with EGFR-mutated non-small cell lung cancer...
Key Takeaways:AstraZeneca's proprietary TROP2-QCS biomarker predicts improved outcomes for NSCLC patients treated with datopotamab deruxtecan.
The biomarker-based analysis shows significantly greater progression-free survival...
Ifinatamab Deruxtecan Shows Promising Results in Small Cell Lung Cancer
Key Takeaways:Ifinatamab deruxtecan demonstrates an objective response rate (ORR) of 54.8% in small cell lung cancer patients.
The 12 mg/kg dose is selected...
Breast cancer patients with unresectable or metastatic HER2 low or HER2 ultralow tumors may soon have access to a promising new treatment option. The...
Daiichi Sankyo and Merck’s Cancer Drug Development Agreement
Daiichi Sankyo and Merck announced the expansion of their global co-development and co-commercialization agreement to include MK-6070 for cancer patients, an investigational delta-like ligand...
The latest update in the field of lung cancer treatment comes as Daiichi Sankyo and Merck announce the initiation of the IDeate-Lung02 Phase 3...
Trastuzumab deruxtecan, known as Enhertu by AstraZeneca and Daiichi Sankyo, is not recommended for treating HER2-low metastatic or unresectable breast cancer after chemotherapy. This...
